Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday

Processa Pharmaceuticals (NASDAQ:PCSA) will likely be releasing its earnings data before the market opens on Friday, April 4th. Analysts expect Processa Pharmaceuticals to post earnings of ($0.92) per share for the quarter.

Processa Pharmaceuticals (NASDAQ:PCSA) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.18. On average, analysts expect Processa Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Processa Pharmaceuticals Stock Down 0.4 %

Shares of PCSA opened at $0.39 on Friday. The stock has a market cap of $1.27 million, a PE ratio of -0.12 and a beta of 0.75. Processa Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $3.31. The business has a 50-day simple moving average of $0.56 and a two-hundred day simple moving average of $0.93.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Processa Pharmaceuticals in a research note on Thursday, December 5th.

Insider Transactions at Processa Pharmaceuticals

In other news, CEO George K. Ng purchased 87,200 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were bought at an average cost of $0.80 per share, with a total value of $69,760.00. Following the completion of the transaction, the chief executive officer now directly owns 87,200 shares of the company’s stock, valued at approximately $69,760. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Young acquired 124,500 shares of Processa Pharmaceuticals stock in a transaction on Monday, January 27th. The stock was purchased at an average cost of $0.80 per share, with a total value of $99,600.00. Following the completion of the transaction, the insider now directly owns 205,405 shares in the company, valued at $164,324. This represents a 153.88 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 224,100 shares of company stock valued at $179,280 over the last ninety days. 13.00% of the stock is owned by company insiders.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.